Unapproved Petitioner: Clinical-Stage Firm Wants FDA Scrutiny Of Naloxone Formulations
Executive Summary
Mucodel has a oromucosal naloxone product in Phase I, and it wants US FDA to reconsider approval standards for intranasal products that are further along in development.
You may also be interested in...
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.
Higher Naloxone Doses Narrowly Favored By FDA Panel
Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.